ArticleFrontiers in cellular and infection microbiology2025
Performance evaluation of a novel RapiSafe HIV Ag/Ab combi rapid test for the detection of HIV antigen and antibodies.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The detection of acute HIV infection (AHI) is vital for timely diagnosis and appropriate management, thus, Methods: Antigen sensitivity was evaluated in 1st WHO International Standard for HIV-1 p24 Antigen (NIBSC 22/230) and Reference Panel (NIBSC 16/210). Five HIV-1 seroconversion panels and one HIV-1 p24 antigen Mixed Titer Performance Panel were detected for HIV-1 p24 antigen seroconversion sensitivity evaluation. 22 treatment-naïve acute HIV-1 serum at Fiebig stage III-VI were detected with both the RapiSafe and the Determine tests. To evaluate the diagnostic sensitivity in different genotypes and specimen types of HIV-1 established infections, HIV positive serum and venous whole blood were detected. Diagnostic specificity was evaluated in clinical serum, plasma, capillary whole blood, and venous whole blood. Results: Compared with the Abbott Determine tests, the RapiSafe showed lower antigen detection limits in HIV-1 subtypes A1, C, and D; higher p24 antigen sensitivity with five more seroconversion reactive detections; and one more antigen-positive AHI serum detection. The superior antigen and antibodies sensitivity of the RapiSafe among serum, plasma, and venous whole blood did not compromise specificity (99.75-100%) among different specimen types with potentially cross-reacting substances or unrelated medical conditions. Conclusion: The exceptional performance of the RapiSafe in antigen and antibodies detection among different subtypes and specimen types makes it a valuable tool in HIV diagnosis. Its novel approach could significantly impact global HIV control by facilitating early detection and timely intervention, which are essential for the uptake of prevention, prompt HIV diagnosis, and mitigating global HIV transmission risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.